CAS

DHT Holdings, Inc. announces $305 million financing

Retrieved on: 
Monday, January 9, 2023

HAMILTON, BERMUDA, January 9, 2023 – DHT Holdings, Inc. (NYSE:DHT) (“DHT” or the “Company”) today announces a new $305 million secured credit facility.

Key Points: 
  • HAMILTON, BERMUDA, January 9, 2023 – DHT Holdings, Inc. (NYSE:DHT) (“DHT” or the “Company”) today announces a new $305 million secured credit facility.
  • It is in line with the “DHT-style financing” including a six-year tenor and a 20-year repayment profile.
  • The new facility will bear interest at a rate equal to Secured Overnight Financing Rate (SOFR) plus a margin of 1.90%, including the historical Credit Adjustment Spread (CAS) of 26 basis points.
  • The new facility will refinance the outstanding amount on the current ABN Amro credit facility and be secured by 10 of the Company’s VLCCs.

KBRA Assigns Preliminary Ratings to Fannie Mae’s CAS 2023-R01

Retrieved on: 
Monday, January 9, 2023

KBRA assigns preliminary ratings to 62 classes from Connecticut Avenue Securities, Series 2023-R01 (CAS 2023-R01), a credit risk sharing transaction with a total note offering of $730,749,000.

Key Points: 
  • KBRA assigns preliminary ratings to 62 classes from Connecticut Avenue Securities, Series 2023-R01 (CAS 2023-R01), a credit risk sharing transaction with a total note offering of $730,749,000.
  • The pool is characterized by loans with original loan-to-value (LTV) ratios that are greater than 60% and less than or equal to 80%.
  • The Reference Pool consists of 67,693 residential mortgage loans with an outstanding principal balance of approximately $22.6 billion as of the cut-off date.
  • The borrowers in the Reference Pool have a non-zero WA (NZWA) original credit score of 747 and a NZWA debt-to-income (DTI) ratio of 36.3%.

Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED)

Retrieved on: 
Sunday, January 8, 2023

WALTHAM, Mass., Jan. 08, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced positive topline clinical data from the third, low dose cohort in its ongoing Phase 1/2 clinical trial of VRDN-001, an anti-insulin-like growth factor 1 receptor (IGF-1R) antibody, in patients with active thyroid eye disease (TED). The Company believes this data further validate the differentiated and potentially best-in-class clinical activity of VRDN-001. The data also support the planned dosing interval for Viridian’s VRDN-002 and VRDN-003 subcutaneous programs of up to once monthly.    

Key Points: 
  • The data also support the planned dosing interval for Viridian’s VRDN-002 and VRDN-003 subcutaneous programs of up to once monthly.
  • The Company previously announced positive results from the first two dose cohorts, which demonstrated a favorable safety profile.
  • The third cohort evaluated a VRDN-001 dose of 3 mg/kg with 6-week data announced today.
  • The Company expects to select either the VRDN-002 or VRDN-003 subcutaneous program to advance to a pivotal Phase 3 trial in early 2024.

Clarivate and the Chinese Academy of Sciences Release Annual Joint Report to Identify 165 Research Fronts

Retrieved on: 
Tuesday, January 3, 2023

LONDON, Jan. 3, 2023 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, and the Chinese Academy of Sciences (CAS) today released Research Fronts 2022, their ninth annual collaborative report. The report identifies significant areas in the world of sciences and social sciences as to where the scientific community is focusing its attention, including several COVID-related fronts and areas mirrored by the research fields of Noble Prize in recent years.

Key Points: 
  • The 2022 report starts with 12,610 Research Fronts in the ESI™ from 2016 to 2021 and aims to discover which Research Fronts were most active or developing most rapidly.
  • This year's report identified 165 Research Fronts, including 110 'hot' and 55 'emerging' fronts spanning in 11 broad areas.
  • Experts at CAS analyzed and interpreted all the Research Fronts to further highlight 32 key Research Fronts and one key Research Front group.
  • In conjunction with the Research Fronts 2022 report, Clarivate and CAS also published 2022 Research Fronts: Active Fields, Leading Countries to examine and compare national performance across the 165 Research Fronts.

Ethyl Maltol (CAS 4940-11-8) Global Market Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Monday, December 19, 2022

The "Ethyl maltol (CAS 4940-11-8) Global Market Research Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Ethyl maltol (CAS 4940-11-8) Global Market Research Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of Ethyl maltol.
  • The fifth chapter deals with Ethyl maltol market trends and forecast, and distinguishes Ethyl maltol manufacturers and suppliers.
  • The Ethyl maltol global market report key points:

PHASE II/III CLINICAL TRIAL OF SIMCERE'S 3CL-TARGETING ANTI-SARS-COV-2 DRUG CANDIDATE COMPLETE ALL PATIENTS ENROLLMENT

Retrieved on: 
Tuesday, December 20, 2022

Simcere will accelerate the analysis of clinical study results and actively prepare for New Drug Application (NDA), while speeding up the expansion of production capacity to meet urgent clinical needs.

Key Points: 
  • Simcere will accelerate the analysis of clinical study results and actively prepare for New Drug Application (NDA), while speeding up the expansion of production capacity to meet urgent clinical needs.
  • This is to fulfill the Group's corporate mission of "providing today's patients with medicines of the future".
  • The Study has established a total of 43 clinical research centers in 20 provinces, municipalities and autonomous regions in China.
  • XIANNUOXIN is a combination packaged drug of a small molecule anti- SARS-CoV-2 drug candidate and Ritonavir, this candidate is targeted 3CL protease which is essential for SARS-CoV-2 viral replication.

Michigan Health Information Network Once Again Achieves DirectTrust™ HISP Accreditation

Retrieved on: 
Wednesday, December 14, 2022

Lansing, Michigan, Dec. 14, 2022 (GLOBE NEWSWIRE) -- The Michigan Health Information Network (MiHIN) today announced it has once again achieved full accreditation through the DirectTrust™ Accreditation Program for Health Information Service Providers (HISPs). DirectTrust is a non-profit healthcare industry alliance created to support secure, identity-verified electronic exchanges of protected health information (PHI) between provider organizations, and between providers and patients, for the purpose of improved coordination of care.

Key Points: 
  • Lansing, Michigan, Dec. 14, 2022 (GLOBE NEWSWIRE) -- The Michigan Health Information Network (MiHIN) today announced it has once again achieved full accreditation through the DirectTrust™ Accreditation Program for Health Information Service Providers (HISPs). DirectTrust is a non-profit healthcare industry alliance created to support secure, identity-verified electronic exchanges of protected health information (PHI) between provider organizations, and between providers and patients, for the purpose of improved coordination of care.
  • “DirectTrust HISP accreditation certifies that an organization has established and upheld a superior level of trust for its stakeholders, which is a significant distinction.
  • The Michigan Health Information Network Shared Services (MiHIN) is Michigan’s state-designated entity for the technical, legal, secure, and private exchange of health information.
  • MIHIN is a 501C3 non-profit, socio-technical collaboration that includes the State of Michigan, Health Information Exchanges, health systems, hospitals, care providers, behavioral health clinics, FQHC’s, PIHPs, health plans/payers, pharmacies, post-acute care, hospices, and the Governor’s Health Information Technology Commission.

Marijuana decriminalization is not associated with a notable increase in traffic accidents, says new actuarial report

Retrieved on: 
Thursday, December 8, 2022

The study did not detect any statistically significant impacts of decriminalization on the car accident fatality rate, insurance claim frequency or average cost per claim, particularly over the long term.

Key Points: 
  • The study did not detect any statistically significant impacts of decriminalization on the car accident fatality rate, insurance claim frequency or average cost per claim, particularly over the long term.
  • Temporal patterns of human activity (such as yearly, weekly and daily cycles) and inclement weather are much better predictors of the vehicle accident experience than marijuana decriminalization.
  • The study overcomes the limitations and disadvantages of earlier research on the effects of marijuana decriminalization by incorporating novel data-driven methodologies.
  • The models used high-resolution weather data to account for the effects of weather factors,” says the report author, Dr. Vyacheslav Lyubchich.

CAS Introducing Transformational Capabilities to Accelerate Life Sciences Innovation

Retrieved on: 
Thursday, December 15, 2022

CAS, a division of the American Chemical Society specializing in scientific information solutions, announced several initiatives to once again transform scientific research, and empower more rapid discovery for life sciences innovation.

Key Points: 
  • CAS, a division of the American Chemical Society specializing in scientific information solutions, announced several initiatives to once again transform scientific research, and empower more rapid discovery for life sciences innovation.
  • CAS is expanding its comprehensive, highly structured, human-curated scientific data with the introduction of life sciences assets.
  • Our goal is to empower every aspect of drug discovery across scientific disciplines, including biology, and this expansion reflects a historic milestone on our path to accelerate life sciences research.
  • CAS recently established a Life Sciences Industry Advisory Board comprising a world-class panel of global thought leaders from commercial, academic, and government organizations.

Forty Starving Sheep Saved from Backyard Slaughter Operation in New York's Hudson Valley

Retrieved on: 
Friday, December 16, 2022

SAUGERTIES, N.Y., Dec. 16, 2022 /PRNewswire/ -- In an extremely rare victory for farm animals, three New York organizations–an animal rescue organization, a law enforcement agency, and a district attorney's office–have secured the release of 40 starving sheep from a backyard slaughter operation.  As the rescued sheep heal, a Christmas "baby boom" is occurring as the sheep give birth to tiny lambs. Ten have been born to date.

Key Points: 
  • As the rescued sheep heal, a Christmas "baby boom" is occurring as the sheep give birth to tiny lambs.
  • Within days of their arrival, three sheep passed away, despite being given blood transfusion from healthy resident sheep.
  • Since the sheep have arrived, CAS is thrilled to announce the birth of ten tiny lambsjust in time for Christmas.
  • Founded in 2001, Catskill Animal Sanctuary is a non-profit, 150-acre refuge in New York's Hudson Valley.